• USFDA audited the Aleor derma facility at Karkhadi without any observations. All facilities are cleared by USFDA.
    • The formulation oral solids facility in Panelav was audited by the USFDA with four procedural observations.
  • India: Again lost market share, now down to 1.5% (Brands in top 300 down from 5 to 3; total 185 which they are not able to ramp up)
    • Chronic therapies account for 65% of domestic revenue and 93% of new launches in the last five years.
    • Per capita sales per month growth will be visible by FY21: Let’s see.
  • R&D team enhanced to 1200: huge Anda filings run rate continues
  • Most of the incremental capacities will be up and running by FY22.
  • US front end:  Revenues have touched over $250 million in the past five years.
  • Planning to deleverage in the future.
  • R&D strength increased to 1100+; continues robust ANDAs filings run rate.